Addeira Pharmaceuticals
Addeira Pharmaceuticals, a prominent player in the pharmaceutical industry, is headquartered in Sweden (SE) and operates extensively across Europe and North America. Founded in 2010, the company has rapidly established itself as a leader in innovative drug development, focusing on therapeutic areas such as oncology and neurology. Addeira's core offerings include advanced biologics and targeted therapies, distinguished by their commitment to enhancing patient outcomes through cutting-edge research and development. The company has achieved significant milestones, including several successful product launches that have garnered recognition within the healthcare community. With a strong market position, Addeira Pharmaceuticals continues to push the boundaries of medical science, striving to deliver unique solutions that address unmet medical needs and improve the quality of life for patients worldwide.
DitchCarbon Score
How does Addeira Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Addeira Pharmaceuticals's score of 29 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Addeira Pharmaceuticals's reported carbon emissions
Addeira Pharmaceuticals, headquartered in Sweden, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, the company has established a target to reduce its Scope 1 and Scope 2 emissions by 42% by the year 2030, using 2022 as the baseline year. This target has been validated through a streamlined process for small and medium-sized enterprises (SMEs) and aligns with the necessary reductions to limit global warming to 1.5°C. In addition to its focus on direct emissions (Scope 1 and 2), Addeira Pharmaceuticals is also committed to measuring and reducing its Scope 3 emissions, which encompass indirect emissions from the value chain. This comprehensive approach reflects the company's dedication to addressing its overall carbon footprint and contributing to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Addeira Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
